Skip to content

Akari Therapeutics, Plc: 20-F filed 2021-04-21

What Akari Therapeutics, Plc reported in its annual report (foreign private issuer) filed 2021-04-21 (fiscal FY 2020): 33 published measures, 254 facts as tagged in accession 0001104659-21-052672.

This filing

Form
20-F (annual report (foreign private issuer))
Filed
2021-04-21
Fiscal period
fiscal FY 2020
Accession
0001104659-21-052672 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Akari Therapeutics, Plc filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-12-3114,604,807USD
At 2020-09-3013,693,716USD
At 2020-06-3014,452,180USD
At 2020-03-319,680,286USD
At 2019-12-316,479,842USD
At 2019-09-3010,267,716USD
At 2019-06-304,612,296USD
At 2019-03-318,229,960USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-12-315,220,488USD
At 2020-09-306,745,417USD
At 2020-06-308,494,766USD
At 2020-03-316,411,697USD
At 2019-12-316,472,244USD
At 2019-09-305,365,336USD
At 2019-06-304,152,929USD
At 2019-03-313,388,410USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-12-319,384,319USD
At 2020-09-306,948,299USD
At 2020-06-305,957,414USD
At 2020-03-313,268,589USD
At 2019-12-317,598USD
At 2019-09-304,902,380USD
At 2019-06-30459,367USD
At 2019-03-314,841,550USD
At 2018-12-314,368,711USD
At 2017-12-3122,235,306USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-12-3114,055,777USD
At 2020-09-3012,317,798USD
At 2020-06-3012,746,266USD
At 2020-03-317,822,180USD
At 2019-12-315,731,691USD
At 2019-09-306,268,667USD
At 2019-06-302,736,663USD
At 2019-03-316,145,555USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-17,081,617USD366
2020-07-01 to 2020-09-30913,454USD92
2020-01-01 to 2020-09-30-10,271,768USD274
2020-04-01 to 2020-06-30-7,439,815USD91
2020-01-01 to 2020-06-30-11,185,222USD182
2020-01-01 to 2020-03-31-3,745,407USD91
2019-01-01 to 2019-12-31-16,846,203USD365
2019-07-01 to 2019-09-30-2,881,894USD92
2019-01-01 to 2019-09-30-9,016,178USD273
2019-04-01 to 2019-06-30-5,947,773USD91
2019-01-01 to 2019-06-30-6,134,284USD181
2019-01-01 to 2019-03-31-186,511USD90
2018-01-01 to 2018-12-31-20,499,459USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-16,950,408USD366
2020-01-01 to 2020-09-30-12,717,287USD274
2020-01-01 to 2020-06-30-12,013,118USD182
2020-01-01 to 2020-03-31-7,739,656USD91
2019-01-01 to 2019-12-31-12,918,313USD365
2019-01-01 to 2019-09-30-9,454,014USD273
2019-01-01 to 2019-06-30-4,543,565USD181
2019-01-01 to 2019-03-31228,944USD90
2018-01-01 to 2018-12-31-22,774,008USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-12-3125,073,961USD366
2020-01-01 to 2020-09-3019,081,460USD274
2020-01-01 to 2020-06-3019,081,460USD182
2020-01-01 to 2020-03-319,877,988USD91
2019-01-01 to 2019-12-3112,647,953USD365
2019-01-01 to 2019-09-309,871,886USD273
2019-01-01 to 2019-06-301,473,828USD181
2019-01-01 to 2019-03-31157,743USD90
2018-01-01 to 2018-12-31500,000USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-12-31-182,280,811USD
At 2020-09-30-175,470,962USD
At 2020-06-30-176,384,416USD
At 2020-03-31-168,944,601USD
At 2019-12-31-165,199,194USD
At 2019-09-30-157,369,170USD
At 2019-06-30-154,487,275USD
At 2019-03-31-148,539,502USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2020-01-01 to 2020-12-313,159,037,588shares366
2019-01-01 to 2019-12-311,830,998,609shares365
2018-01-01 to 2018-12-311,540,309,840shares365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2020-01-01 to 2020-12-313,159,037,588shares366
2019-01-01 to 2019-12-311,830,998,609shares365
2018-01-01 to 2018-12-311,540,309,840shares365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-01-01 to 2020-12-310USD366
2019-01-01 to 2019-12-310USD365
2018-01-01 to 2018-12-310USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-12-310USD
At 2020-03-312,096USD
At 2019-12-315,013USD
At 2019-09-308,388USD
At 2019-06-3012,056USD
At 2019-03-3115,834USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-01-01 to 2020-12-31325,523USD366
2020-01-01 to 2020-09-30244,941USD274
2020-01-01 to 2020-06-30163,834USD182
2020-01-01 to 2020-03-31100,504USD91
2019-01-01 to 2019-12-311,047,387USD365
2019-01-01 to 2019-09-30941,446USD273
2019-01-01 to 2019-06-30804,061USD181
2019-01-01 to 2019-03-31394,439USD90
2018-01-01 to 2018-12-311,649,044USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-17,980,974USD366
2020-07-01 to 2020-09-30-246,883USD92
2020-01-01 to 2020-09-30-11,085,466USD274
2020-04-01 to 2020-06-30-5,911,609USD91
2020-01-01 to 2020-06-30-10,838,583USD182
2020-01-01 to 2020-03-31-4,926,974USD91
2019-01-01 to 2019-12-31-16,963,120USD365
2019-07-01 to 2019-09-30-3,117,320USD92
2019-01-01 to 2019-09-30-9,136,805USD273
2019-04-01 to 2019-06-30-6,031,447USD91
2019-01-01 to 2019-06-30-6,019,485USD181
2019-01-01 to 2019-03-3111,962USD90
2018-01-01 to 2018-12-31-20,785,302USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-12-3114,577,657USD
At 2020-09-3013,667,042USD
At 2020-06-3014,425,691USD
At 2020-03-319,650,624USD
At 2019-12-316,444,666USD
At 2019-09-3010,230,181USD
At 2019-06-304,551,811USD
At 2019-03-318,033,335USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-12-313,380,782USD
At 2020-09-302,410,530USD
At 2020-06-302,191,168USD
At 2020-03-31966,059USD
At 2019-12-311,228,772USD
At 2019-09-301,315,411USD
At 2019-06-301,481,536USD
At 2019-03-311,763,182USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-01-01 to 2020-12-3117,980,974USD366
2020-07-01 to 2020-09-30246,883USD92
2020-01-01 to 2020-09-3011,085,466USD274
2020-04-01 to 2020-06-305,911,609USD91
2020-01-01 to 2020-06-3010,838,583USD182
2020-01-01 to 2020-03-314,926,974USD91
2019-01-01 to 2019-12-3116,963,120USD365
2019-07-01 to 2019-09-303,117,320USD92
2019-01-01 to 2019-09-309,136,805USD273
2019-04-01 to 2019-06-306,031,447USD91
2019-01-01 to 2019-06-306,019,485USD181
2019-01-01 to 2019-03-31-11,962USD90
2018-01-01 to 2018-12-3120,785,302USD365

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2020-01-01 to 2020-12-319,160,770USD366
2020-07-01 to 2020-09-301,839,414USD92
2020-01-01 to 2020-09-306,925,400USD274
2020-04-01 to 2020-06-302,891,177USD91
2020-01-01 to 2020-06-305,085,986USD182
2020-01-01 to 2020-03-312,194,809USD91
2019-01-01 to 2019-12-318,223,700USD365
2019-07-01 to 2019-09-301,354,263USD92
2019-01-01 to 2019-09-306,098,767USD273
2019-04-01 to 2019-06-302,438,106USD91
2019-01-01 to 2019-06-304,744,504USD181
2019-01-01 to 2019-03-312,306,398USD90
2018-01-01 to 2018-12-3111,689,926USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-01-01 to 2020-12-318,820,204USD366
2019-01-01 to 2019-12-318,739,420USD365
2018-01-01 to 2018-12-3111,795,376USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-12-313,847,331,923shares
At 2019-12-312,245,865,913shares
At 2018-12-31312,019shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2020-12-3114,055,777USD
At 2020-09-3012,317,798USD
At 2020-06-3012,746,266USD
At 2020-03-317,822,180USD
At 2019-12-315,731,691USD
At 2019-09-306,268,667USD
At 2019-06-302,754,027USD
At 2019-03-316,293,479USD
At 2018-12-315,967,967USD
At 2017-12-3128,248,906USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2020-12-31-648,065USD
At 2020-09-30-621,298USD
At 2020-06-30-617,622USD
At 2020-03-31-571,585USD
At 2019-12-31-348,860USD
At 2019-09-30-402,093USD
At 2019-06-30-405,374USD
At 2019-03-31-245,258USD
At 2018-12-31-352,426USD
At 2017-12-31-236,246USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2020-12-31164,938USD
At 2019-12-31164,938USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2020-12-31164,938USD
At 2019-12-31159,925USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2020-12-3127,150USD
At 2020-09-3026,674USD
At 2020-06-3026,489USD
At 2020-03-3127,566USD
At 2019-12-3130,163USD
At 2019-09-3029,147USD
At 2019-06-3031,065USD
At 2019-03-3132,867USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2020-12-311,839,706USD
At 2020-09-30975,893USD
At 2020-06-301,941,083USD
At 2020-03-312,630,857USD
At 2019-12-314,228,604USD
At 2019-09-303,035,056USD
At 2019-06-302,671,393USD
At 2019-03-311,625,228USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2020-12-31521,880USD
At 2020-09-301,349,244USD
At 2020-06-301,679,425USD
At 2020-03-311,828,444USD
At 2019-12-31712,975USD
At 2019-09-301,058,527USD
At 2019-06-301,747,365USD
At 2019-03-311,887,780USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-17,081,617USD366
2019-01-01 to 2019-12-31-16,846,203USD365
2018-01-01 to 2018-12-31-20,499,459USD365

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-17,380,822USD366
2020-07-01 to 2020-09-30909,778USD92
2020-01-01 to 2020-09-30-10,544,206USD274
2020-04-01 to 2020-06-30-7,485,852USD91
2020-01-01 to 2020-06-30-11,453,984USD182
2020-01-01 to 2020-03-31-3,968,132USD91
2019-01-01 to 2019-12-31-16,842,637USD365
2019-07-01 to 2019-09-30-2,878,613USD92
2019-01-01 to 2019-09-30-9,065,845USD273
2019-04-01 to 2019-06-30-6,107,889USD91
2019-01-01 to 2019-06-30-6,187,232USD181
2019-01-01 to 2019-03-31-79,343USD90
2018-01-01 to 2018-12-31-20,615,639USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2020-01-01 to 2020-12-318,907USD366
2020-01-01 to 2020-09-307,907USD274
2020-01-01 to 2020-06-306,921USD182
2020-01-01 to 2020-03-313,877USD91
2019-01-01 to 2019-12-3119,205USD365
2019-01-01 to 2019-09-3014,892USD273
2019-01-01 to 2019-06-3010,266USD181
2019-01-01 to 2019-03-315,566USD90
2018-01-01 to 2018-12-3135,848USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2020-01-01 to 2020-12-31899,357USD366
2020-07-01 to 2020-09-301,160,337USD92
2020-01-01 to 2020-09-30813,698USD274
2020-04-01 to 2020-06-30-1,528,206USD91
2020-01-01 to 2020-06-30-346,639USD182
2020-01-01 to 2020-03-311,181,567USD91
2019-01-01 to 2019-12-31116,917USD365
2019-07-01 to 2019-09-30235,426USD92
2019-01-01 to 2019-09-30120,627USD273
2019-04-01 to 2019-06-3083,674USD91
2019-01-01 to 2019-06-30-114,799USD181
2019-01-01 to 2019-03-31-198,473USD90
2018-01-01 to 2018-12-31285,843USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2020-01-01 to 2020-12-3125,046,461USD366
2020-01-01 to 2020-09-3019,053,960USD274
2020-01-01 to 2020-06-3019,053,960USD182
2020-01-01 to 2020-03-317,095,368USD91
2019-01-01 to 2019-12-3112,647,953USD365
2019-01-01 to 2019-09-309,871,886USD273
2019-01-01 to 2019-06-301,473,828USD181
2019-01-01 to 2019-03-31157,743USD90
2018-01-01 to 2018-12-31500,000USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-09-302,902,987USD273

Inspect the source

Entity
Akari Therapeutics, Plc / CIK 0001541157
Captured
2026-09-20T09:17:38.520Z
SEC response SHA-256
28aa6200c3956b4742e82320b97671468c61e673338f20b4055d5cab77ff39a0

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001541157.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))